MiMedx addressed reimbursement fears on call, says Craig-Hallum Craig-Hallum said MiMedx management outlined reimbursement scenarios for when the company no longer has pass-through status, calming the fears of some investors. Craig-Hallum also noted that the company raised the lower-end of its FY14 revenue guidance to $95M from $90M and that management said its meeting with the FDA about its micronized injectable products was both "productive and helpful." The firm reiterates its Buy rating and $10 price target on MiMedx.
Piper Jaffray and the Alliance for Regenerative Medicine co-host conference 3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link